In an unusual move, federal health officials narrowed their recommendations for who should receive the vaccine against the respiratory syncytial virus. The Centers for Disease Control and Prevention advised last year that adults age 60 or older could receive a single lifetime dose of an R.S.V. vaccine, in consultation with their health care providers. On…
Vaccines for respiratory syncytial virus may have caused a few cases of Guillain-Barré syndrome, a rare neurological condition, federal health officials said on Thursday. The numbers were small, on the order of two cases per 100,000 vaccinated people or fewer, and much more data is needed to pin down the risk, the officials said. In…
This winter, for the first time ever, there were two vaccines available to ward off respiratory syncytial virus, which is particularly dangerous to older adults and infants. Only one of them — Abrysvo, made by Pfizer — was approved for pregnant women, and neither was for young children. The distinction apparently slipped by some clinicians…
